Citadel Advisors’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $333K | Sell |
5,900
-1,700
| -22% | -$111K | ﹤0.01% | 10244 |
|
|
2025
Q4 | $609K | Sell |
7,600
-8,800
| -54% | -$591K | ﹤0.01% | 8561 |
|
|
2025
Q3 | $799K | Buy |
16,400
+11,800
| +257% | +$730K | ﹤0.01% | 8037 |
|
|
2025
Q2 | $343K | Sell |
4,600
-4,300
| -48% | -$285K | ﹤0.01% | 9488 |
|
|
2025
Q1 | $566K | Sell |
8,900
-28,000
| -76% | -$1.9M | ﹤0.01% | 8215 |
|
|
2024
Q4 | $2.88M | Buy |
36,900
+21,600
| +141% | +$1.73M | ﹤0.01% | 4906 |
|
|
2024
Q3 | $1.23M | Buy |
15,300
+6,100
| +66% | +$493K | ﹤0.01% | 6438 |
|
|
2024
Q2 | $761K | Sell |
9,200
-1,000
| -10% | -$88K | ﹤0.01% | 7157 |
|
|
2024
Q1 | $871K | Buy |
10,200
+7,400
| +264% | +$581K | ﹤0.01% | 7216 |
|
|
2023
Q4 | $239K | Sell |
2,800
-1,800
| -39% | -$156K | ﹤0.01% | 9604 |
|
|
2023
Q3 | $412K | Buy |
4,600
+300
| +7% | +$26.8K | ﹤0.01% | 8500 |
|
|
2023
Q2 | $366K | Sell |
4,300
-11,700
| -73% | -$989K | ﹤0.01% | 8605 |
|
|
2023
Q1 | $1.32M | Buy |
16,000
+11,100
| +227% | +$899K | ﹤0.01% | 6179 |
|
|
2022
Q4 | $385K | Buy |
4,900
+1,100
| +29% | +$88.4K | ﹤0.01% | 8796 |
|
|
2022
Q3 | $281K | Sell |
3,800
-4,900
| -56% | -$352K | ﹤0.01% | 9722 |
|
|
2022
Q2 | $567K | Sell |
8,700
-1,900
| -18% | -$112K | ﹤0.01% | 8367 |
|
|
2022
Q1 | $670K | Sell |
10,600
-33,300
| -76% | -$1.81M | ﹤0.01% | 8670 |
|
|
2021
Q4 | $2.33M | Buy |
43,900
+30,900
| +238% | +$1.88M | ﹤0.01% | 5892 |
|
|
2021
Q3 | $918K | Sell |
13,000
-14,500
| -53% | -$915K | ﹤0.01% | 8371 |
|
|
2021
Q2 | $1.83M | Buy |
27,500
+18,800
| +216% | +$1.33M | ﹤0.01% | 6820 |
|
|
2021
Q1 | $966K | Sell |
8,700
-1,700
| -16% | -$210K | ﹤0.01% | 8204 |
|
|
2020
Q4 | $1.24M | Buy |
10,400
+4,200
| +68% | +$452K | ﹤0.01% | 6343 |
|
|
2020
Q3 | $541K | Sell |
6,200
-500
| -7% | -$43.7K | ﹤0.01% | 7157 |
|
|
2020
Q2 | $600K | Buy |
6,700
+2,400
| +56% | +$242K | ﹤0.01% | 6740 |
|
|
2020
Q1 | $429K | Buy |
+4,300
| New | +$466K | ﹤0.01% | 6715 |
|
|
2019
Q4 | – | Sell |
-1,900
| Closed | -$240K | – | 9356 |
|
|
2019
Q3 | $240K | Sell |
1,900
-600
| -24% | -$76.2K | ﹤0.01% | 7897 |
|
|
2019
Q2 | $301K | Buy |
2,500
+100
| +4% | +$9.84K | ﹤0.01% | 7579 |
|
|
2019
Q1 | $210K | Sell |
2,400
-4,100
| -63% | -$373K | ﹤0.01% | 8142 |
|
|
2018
Q4 | $650K | Sell |
6,500
-5,200
| -44% | -$546K | ﹤0.01% | 5989 |
|
|
2018
Q3 | $1.34M | Sell |
11,700
-98,500
| -89% | -$10.2M | ﹤0.01% | 5046 |
|
|
2018
Q2 | $9.88M | Buy |
+110,200
| New | +$9.31M | ﹤0.01% | 1946 |
|
Other funds holding HAE
VPM
VCM
RRAM
Citadel Advisors's HAE Position: Q1 2026 in Review
Citadel Advisors reduced its Haemonetics (HAE) stake by 80% in Q1 2026, selling an estimated $67.1M and leaving 258,153 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2722.
Citadel Advisors first reported a position in HAE in Q2 2013 and has held it in 45 quarters since. The position peaked at $103M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Citadel Advisors held 258,153 shares of Haemonetics worth $14.5M as of Q1 2026.
- Citadel Advisors sold 1,030,279 Haemonetics shares in Q1 2026, an estimated $67.1M.
- Haemonetics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2722 holding.
- Citadel Advisors first reported a position in Haemonetics in Q2 2013 and has held it in 45 quarters since.
- Citadel Advisors's Haemonetics position peaked at $103M in Q4 2025.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.